Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 4/20 | 0.54 |
| ▸ | PRKCA | P17252 | 6/20 | 0.51 |
| ▸ | TLR4 | O00206 | 4/20 | 0.49 |
| ▸ | LY96 | Q9Y6Y9 | 4/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10325676 | 1.00 | TK2 (0.54) | TK2PRKCATLR4LY96LGALS8 | |
| SCHEMBL10325164 | 1.00 | TK2 (0.54) | TK2PRKCATLR4LY96LGALS8 | |
| SCHEMBL2201385 | 1.00 | TK2 (0.54) | TK2PRKCATLR4LY96LGALS8 | |
| SCHEMBL2199694 | 1.00 | TK2 (0.54) | TK2PRKCATLR4LY96LGALS8 | |
| SCHEMBL2201391 | 1.00 | TK2 (0.54) | TK2PRKCATLR4LY96LGALS8 | |
| SCHEMBL2199693 | 1.00 | TK2 (0.54) | TK2PRKCATLR4LY96LGALS8 | |
| SCHEMBL10325678 | 1.00 | TK2 (0.54) | TK2PRKCATLR4LY96LGALS8 | |
| SCHEMBL10325165 | 1.00 | TK2 (0.54) | TK2PRKCATLR4LY96LGALS8 | |
| SCHEMBL10326198 | 0.94 | LGALS8 (0.49) | TK2PRKCATLR4LY96LGALS8 | |
| SCHEMBL10326200 | 0.94 | LGALS8 (0.49) | TK2PRKCATLR4LY96LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130134-A1 | METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-04-27 | — | — | US | disclosed |
| EP-4121060-A1 | METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF | Board of Regents, The University of Texas System (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021188586-A1 | METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-09-23 | — | — | WO | disclosed |
| EP-2663314-A2 | MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES | The University of Texas M.D. Anderson Cancer (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20120276108-A1 | MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES | INTERTECH BIO (US) | 2012-11-01 | — | — | US | disclosed |
| WO-2012097052-A2 | MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES | INTERTECH BIO, LLC (US) | 2012-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130134-A1 | METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF | G6PD, FBP1, ALDOA | TK2 237/4885PRKCA 3265/4885TLR4 658/4885 |
| US-20120276108-A1 | MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES | IGF1R, IRS1, IGFBP1 | TK2 238/4885PRKCA 1662/4885TLR4 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.